accurately benign lesions than are their general practitioners or other medical personnel. Finally, we followed up 97%O of the original study population, compared with 63%/ in the Chicago study. Clearly more information is needed on the occurrence of benign uterine tumours in women exposed to oestrogens, with and without progestogens, particularly as these lesions may be precursors of malignant disease.
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We must emphasise that the doses of hormones to which the pregnant women were exposed were massive. The average dose of stilboestrol was estimated to be 16-3 g and of ethisterone 13-8 g. In the Chicago study the women were exposed to about 11 g of stilboestrol.5 Stilboestrol when given for menopausal symptoms is usually administered as a daily dose of 0 5 mg. Thus the average dose accumulated by the pregnant women in our study was equivalent to more than 80 years of continuous menopausal oestrogen treatment. None the less, the incidence of breast cancer was high, 50' of the treated group having already developed breast cancer although the average age of those who were still alive was only 55-8 years. Interestingly, no breast cancer occurred until 18 years after treatment; a similarly long latent period was evident in the Chicago study. Another study of breast cancer and menopausal oestrogen use found an increased risk of breast cancer after a delay of 15 years or longer." Although breast cancer has been reported in association with stilboestrol treatment alone, our findings suggest that stilboestrol in combination with ethisterone may have a similar effect. It is obviously impossible to know whether the induction of breast cancer by hormonal treatment is specific for high doses given to pregnant women or whether it may also occur when lower doses are given to non-pregnant women. If it does occur in non-pregnant women, these results, the Chicago findings, and observations in menopausal women all suggest that the induction period may be 15 years or longer. 2 
Results
Patients-The 27 patients (17 men) had a mean age of 54 years (range 34-70); three had renal hypertension. Sixteen patients suffered complications of hypertension, and seven had renal impairment (serum creatinine ,umol/l (1-5-4-1 mg/100 ml)). Immediately before diuretic treatment was changed the mean blood pressure was 190/110 mm Hg lying, with a mean arterial pressure of 120 mm Hg or more in all (range 120-157 mm Hg) while they were taking three (16) or four (11) antihypertensive drugs including the thiazide diuretic.
The other drugs (and mean daily doses) were as follows: 26 patients were taking beta-blockers, 15 hydrallazine (200 mg), 11 methyldopa (1700 mg), 7 prazosin (10 mg), 3 debrisoquine (80 mg), 2 bethanidine (75 mg), and 1 guanethidine (100 mg). These drugs were not changed. Two patients had ankle swelling and none had cardiac failure.
Evidence for resistant hypertension-At the three visits before the change of diuretic treatment, spanning an average of 12 weeks, blood pressure and body weight remained constant (table I) . During this time antihypertensive treatment was increased 28 times in 20 patients, which produced a mean reduction at the next visit of 4-8/1-8 mm Hg recumbent, which was not significant. In five patients a new drug had been introduced and produced a mean increase of 2-2/1-0 mm Hg.
Response to frusemide and spironolactone-Frusemide was substituted for the thiazide in 16 
Discussion
In this type of survey it is often difficult to be sure that apparent responses to treatment are not due to phenomena such as regression to the mean, placebo effect, or observer bias. Our data are sufficient to exclude regression to the mean, while placebo effect and observer bias are unlikely for several reasons. These patients were long accustomed to the clinic routine, had been treated by the same doctors throughout, and had not responded to many increases of treatment. At the time frusemide and spironolactone were prescribedwe had no intention of surveying the outcome of changing diuretic treatment. Finally, the highly significant fall in body weight is not readily explained by placebo effect or observer bias.
Addition of spironolactone to the thiazide, or substitution of frusemide, produced highly significant reductions in blood pressure and body weight in these patients with resistant hypertension.' In 40% the lying mean arterial pressure was reduced below 120 mm Hg (equivalent to 160/100 mm Hg), and this would generally be accepted as adequate control. As in other studies,9 10 the response was sustained for at least three months. The response to frusemide (18/ The results support the contention that expansion of the plasma or extracellular fluid volume is often a factor in resistance to treatment.7 9-11 Such expansion occurs despite the use of a thiazide, in the absence of clinical evidence of fluid retention, in patients with normal renal function, and in patients taking antihypertensive drugs of only moderate potency. Increased diuretic treatment is worth trying before resorting to potent drugs such as postganglionic adrenergic blockers or minoxidil in resistant hypertension. If false tolerance is present a postganglionic adrenergic blocker will cause further volume expansion and is unlikely to lower the blood pressure. Minoxidil will reduce the blood pressure in the face of expanded plasma and extracellular fluid volumes,20 but concurrent use of high doses of diuretics is almost invariably needed. It would be sensible to observe first the effect of increased diuretic treatment alone.
The optimal method of using diuretics in resistant hypertension is not established. The effect of frusemide as a single daily dose seems satisfactory,21 but it is not clear whether it should be added5 9 or substituted,7 given continuously9 10 or intermittently,5 or whether it is more5 or less11 effective than spironolactone. At present we suggest that compliant patients resistant to an adequate regimen of three drugs should have frusemide 80 mg or spironolactone 100 mg added to the thiazide. Frusemide should be used when there is renal impairment (serum creatinine >130 ,tmol/l). If the patient does not respond the dose of frusemide or spironolactone may be increased according to tolerance until weight loss of 1 kg is attained, before abandoning the manoeuvre as ineffective. Urea and electrolyte concentrations should be monitored whichever diuretic is added.
Introduction
In any series of drowned or near-drowned individuals, patients are described who initially respond well to resuscitation but whose respiratory function deteriorates over the next few hours. The phenomenon is well known from case reports,'-4 and is thought to be due to loss of surfactant from chemical, anoxic, or osmotic damage to the pneumatocytes that line the alveoli. It may be fatal in both children5 and adults' and is one of the causes of "delayed death subsequent to near-drowning. "' This phenomenon has been called "secondary drowning"3 7-and is characterised by a latent period of several hours,4 or even longer.2 810 The syndrome may be defined as the occurrence of respiratory deterioration after successful resuscitation owing to primary alveolar membrane dysfunction. Estimates of its frequency have been unsatisfactory because of case selection, but the syndrome is thought to occur in at least 2% of sea water neardrownings. " 1 The syndrome has occurred after both fresh water"7 and salt water immersions.' 2 As part of the Brisbane Drowning Study'2'14 we have encountered several examples of this phenomenon. Some children responded so well to rescue-site resuscitation that they were not initially admitted to hospital, only to be found in grave respiratory distress several hours later. This report describes five cases of
